Caplin Point Laboratories Limited Estimates – NSE:CAPLIPOINT
NiveshIQ
NSE: CAPLIPOINT · Healthcare
Caplin Point Laboratories Ltd.
₹2,336.40▲ ₹10.80 (+0.46%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on CAPLIPOINT. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Caplin Point Laboratories Ltd.
Caplin Point Laboratories Limited (CAPLIPOINT) is a Chennai‑based generic pharmaceutical company that designs, manufactures, markets and exports a broad portfolio of formulations including tablets, capsules, injections, ophthalmic preparations, inhalers and IV infusions. The company’s revenue drivers are its high‑volume generic drug sales, with a reported ₹2287 Cr in the latest fiscal year, and a growing presence in branded products. Recent filings show a Q2 FY27 Reg 74(5) certificate and continued disclosure of financial statements, indicating stable regulatory compliance. CAPLIPOINT competes with other Indian generics such as Neuland Laboratories, leveraging cost‑effective production and a diversified product mix to maintain market share. Net income of ₹665 Cr reflects efficient cost man
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹1,694 Cr +15.50% | ₹1,937 Cr +14.37% | ₹2,187 Cr +12.89% |
| EBITDA Margin | 32.55% | 33.39% | 34.79% |
| Net Profit | ₹457.08 Cr +21.48% | ₹563.38 Cr +23.26% | ₹641.24 Cr +13.82% |
| EPS | ₹60.19 | ₹70.57 | ₹84.36 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
Caplin Point Laboratories Limited Estimates – NSE:CAPLIPOINT
Caplin Point Laboratories (CAPLIPOINT.NS) Edges Up 0.54% to Hold Above ₹2,300 - Dealer Positioning
🔒
+ 3 more stories about Caplin Point Laboratories Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹610 Cr, PAT ₹177 Cr, EPS ₹23.27, EBITDA margin 35.0%. Growth context: revenue YoY +19.6%, PAT YoY +15.8%, revenue QoQ +1.7%, PAT QoQ +4.0%.
Test volumes, test mix, B2B/reference‑lab traction, pricing discipline and operating leverage will drive performance ove...
FY26 (last completed FY): revenue ₹2, 187 Cr, PAT ₹641 Cr, EBITDA margin 34.8%, EPS ₹84.36. Year-on-year: revenue YoY +1...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for CAPLIPOINT
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track CAPLIPOINT alongside your other holdings
Unlock full CAPLIPOINT research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Caplin Point Laboratories Ltd.?
NiveshIQ detects active intelligence signals for Caplin Point Laboratories Ltd. (CAPLIPOINT) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Caplin Point Laboratories Ltd.?
Caplin Point Laboratories Ltd. operates in the Healthcare sector with a market capitalisation of ₹1,410,777.1L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.